A high incidence of multiple primary neoplasms has been observed in our patients with ATL in comparison to persons with other forms of hematologic malignancy who we have observed during the past 23 years (1963-1985). Five of 15 patients with ATL (33.3 per cent) have had at least one other associated neoplasm in comparison to only 44 of 1156 patients with other forms of hematological malignancy (3.8 per cent). The incidence figures for secondary neoplasms associated with the other hematologic malignancies were 4.3 per cent (16/370) for acute non-lymphocytic leukemia (ANLL), 2.2 per cent (2/90) for acute lymphocytic leukemia (ALL), 4.8 per cent (1/21) for acute unclassifiable leukemia, 2.2 per cent (5/225) for chronic myelogenous leukemia, 4.7 per cent (2/43) for chronic lymphocytic leukemia, 5.9 per cent (8/136) for malignant monoclonal gammopathy and 3.7 per cent (10/271) for malignant lymphoma. The incidence of multiple neoplasms in patients with ATL in comparison to those with other hematological malignancies was statistically significant (p < 0.01 or p < 0.001). The neoplasms associated with ATL have been adenocarcinoma of the thyroid or stomach, and squamous cell carcinoma of the larynx, lip or lung. We identified ATL-derived factor (ADF) in the cytoplasm of the secondary neoplasms of the ATL patients by means of indirect immunofluoroscopy and immunohistochemical techniques utilizing anti-ADF antibody. We also identified ras p21 products in these neoplasms by means of p21 ras monoclonal antibody studies. The possibility that HTLV-I was the cause of the secondary neoplasms thus was investigated. HTLV-I provirus genome was not found in all the six cases of non-ATL leukemic cells of the patients with anti-HTLV-I antibodies as determined by means of Southern blot analysis utilizing pX DNA probe. These findings suggest that there is some association between ATL cells and pre-malignant cells through ADF or other unknown factors in the activation of ras oncogenes. Subsequent suppression of host immune defence mechanisms in ATL patients permits evolution of the secondary neoplasms.

Adenocarcinoma↗

PubMedDate not supplied

Quantitative assays of idiotype-bearing IgE antibodies.

The present report describes a method allowing quantitation of anti-arsonate IgE antibodies and the estimation of the fraction of such antibodies which expresses the recurring CRIA idiotypic determinant. This method permits an analysis of the regulation of this idiotype within IgE-type antibodies.

Animals↗

PubMedDate not supplied

Mouse Ia antigens are receptors for lactate dehydrogenase virus.

Infection of mice with lactate dehydrogenase virus (LDV) leads to elevation of plasma lactate dehydrogenase, lifelong viraemia and perturbations of cell-mediated and humoral immune responses. The virus replicates exclusively in a restricted set of macrophages, but the basis for restricted cell susceptibility is unknown. By immunofluorescence techniques we have found that the per cent infected was the same as the per cent expressing antigens encoded by the I region of the major histocompatibility complex (Ia). Infection of CBA strain I-A+ peritoneal macrophages was blocked when cells were treated simultaneously with monoclonal antibody to I-A and I-E, but not with either antibody separately. LDV infectivity was inactivated when virus was treated with purified rat glycoprotein homologous to mouse I-A and I-E antigens. These results indicate that the receptors for LDV are I-A and I-E antigens. Selective infection of Ia-positive macrophages may have an important effect on the immunological capability of infected mice.

Animals↗

PubMedDate not supplied

Linkage disequilibrium and association with methamphetamine dependence/psychosis of mu-opioid receptor gene polymorphisms.

Several studies indicate that the mu-opioid receptor plays a role in addiction not only to opiate drugs but also to alcohol and non-opiate addictive drugs. Our studies aim to reveal the associations between gene polymorphisms and methamphetamine (MAP) dependence/psychosis. We newly identified several polymorphisms and four substantial linkage disequilibrium (LD) blocks in the mu-opioid receptor (OPRM1) gene. We found significant differences in both genotype and allele frequencies of the single-nucleotide polymorphism (SNP) IVS2+G691C between control (n=232) and MAP-dependent/psychotic patients (n=128). There was also a significant association between IVS2+G691C and patients with transient psychosis. These results suggest that the OPRM1 gene variations may be a factor in development and prognosis of MAP psychosis.

Adult↗

PubMedDate not supplied

Long-term use of low molecular weight heparin ameliorates hyperlipidemia in patients on hemodialysis.

Hyperlipidemia is one of the major risk factors for cardiovascular death in long-term hemodialysis (HD) patients. To clarify whether unfractionated heparin (UFH) contributes to the pathogenesis of hyperlipidemia, nine Type IIb, seven Type IV, and 10 normolipidemic patients, who had been dialyzed with 80.7 IU/Kg heparin, were dialyzed with 40 anti-Xa U/kg of low molecular weight heparin (LMWH) (Logiparin, Novo-Nordisk, Gentfe, Denmark) for 6 months. Seven normolipidemic patients were also dialyzed with heparin as controls. Decreases in triglyceride (TG) during HD with LMWH were significantly less than those with heparin. However, lipoprotein lipase activities (LPL) during HD with LMWH and heparin, and those before and after 6 months on LMWH, were no different. During the 6 months on LMWH, serum total cholesterol, TG, and alpha lipoprotein significantly decreased in Type IIb patients but did not change in Type IV. In contrast, beta lipoprotein slightly increased in Types IIb, IV, and normolipidemic patients who were dialyzed with LMWH but was unchanged in the controls. These observations suggest that UFH aggravates hyperlipidemia in patients, but these effects cannot be attributed to depletion of endothelial LPL liberated by UFH.

Adult↗

PubMedDate not supplied

Spot scanning system for proton radiotherapy.

In order to provide a uniform and desirable dose distribution over a large radiation field, spot beam scanning is one of the most useful methods. A new spot beam scanning system was constructed for a 70 MeV proton beam. The lateral dose distribution was uniform with +/- 2.5% for an 18 cm square field. It was possible to control the dose at each point in the radiation field by this spot scanning method. This system has been confirmed to be satisfactory for delivering a proton beam in the desired field shape and dose level.

Particle Accelerators↗

PubMedDate not supplied

Broad beam three-dimensional irradiation for proton radiotherapy.

A three-dimensional irradiation system using scatterers for lateral spreading is proposed. This system, which is applicable to proton beams, is easily achieved by ordinary techniques using a movable multileaf collimator, a variable thickness water column, and a computer for their control. Target volumes of convex shape can be irradiated in a three-dimensional way by this method.

Protons↗

PubMedDate not supplied

Compensation for beam intensity fluctuation in determination of P(ion) the ion-recombination correction factor for ionization chambers, by the two-voltage technique.

We have developed a method of compensation for fluctuations in beam intensity that may occur during measurement of Pion, the ion-recombination correction factor, by the two-voltage technique. The method requires signals proportional to beam intensity during measurement. We used a parallel-plate ionization chamber, whose Pion was known, and a vacuum chamber to obtain signals that were proportional to the beam intensity. Experiments were conducted using pulsed proton beam providing doses that ranged from 0.16 to 0.01 cGy/pulse. The value of Pion of a thimble ionization chamber was measured. With these measurements, the validity of the method which we proposed for pulsed beam was verified experimentally.

Particle Accelerators↗